Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44)
This Funding Opportunity Announcement (FOA) solicits Direct to Phase II R44 SBIR grant applications from small businesses to develop novel technologies that will enable new approaches to DNA and direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.
General information about this opportunity
Last Known Status
Active
Program Number
RFA-HG-15-039 Federal Agency/Office
Agency: Department of Health and Human ServicesOffice: National Institutes of Health
Type(s) of Assistance Offered
Grant Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. What is the process for applying and being award this assistance?
Deadlines
08/07/2016 Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements. Who do I contact about this opportunity?
Headquarters Office
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
Website Address
http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-15-039.html
E-mail Address
FBOWebmaster@OD.NIH.GOV
Financial Information
Obligations
$0.00
